Why Is Alzheimer’s-Focused Annovis Bio Stock Nosediving On Monday?
Annovis Bio faces setbacks in Phase 2/3 Alzheimer's study, revealing minimal change in patients' conditions. Despite slight improvements in mild cases, results show no significant difference in treatment groups.